These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 10469452

  • 1. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
    Järvinen TA, Tanner M, Bärlund M, Borg A, Isola J.
    Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
    [Abstract] [Full Text] [Related]

  • 2. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
    Jacobson KK, Morrison LE, Henderson BT, Blondin BA, Wilber KA, Legator MS, O'Hare A, Van Stedum SC, Proffitt JH, Seelig SA, Coon JS.
    Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
    [Abstract] [Full Text] [Related]

  • 3. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K, Trojanec R, Kolár Z, Cwiertka K, Cernáková I, Mihál V, Hajdúch M.
    Neoplasma; 2006 May; 53(5):393-401. PubMed ID: 17013533
    [Abstract] [Full Text] [Related]

  • 4. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE, Parkes RK, Andrulis I, O'Malley FP.
    Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
    [Abstract] [Full Text] [Related]

  • 5. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer.
    Tanner M, Järvinen P, Isola J.
    Cancer Res; 2001 Jul 15; 61(14):5345-8. PubMed ID: 11454672
    [Abstract] [Full Text] [Related]

  • 6. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
    Hicks DG, Yoder BJ, Pettay J, Swain E, Tarr S, Hartke M, Skacel M, Crowe JP, Budd GT, Tubbs RR.
    Hum Pathol; 2005 Apr 15; 36(4):348-56. PubMed ID: 15891995
    [Abstract] [Full Text] [Related]

  • 7. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.
    Taiwan J Obstet Gynecol; 2007 Jun 15; 46(2):146-51. PubMed ID: 17638622
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
    Meng H, Chen R, Li W, Xu L, Xu L.
    Pathol Int; 2012 Jun 15; 62(6):391-9. PubMed ID: 22612507
    [Abstract] [Full Text] [Related]

  • 11. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
    Park K, Han S, Gwak GH, Kim HJ, Kim J, Kim KM.
    Breast Cancer Res Treat; 2006 Aug 15; 98(3):337-42. PubMed ID: 16502015
    [Abstract] [Full Text] [Related]

  • 12. Aberrations of ERBB2 and TOP2A genes in breast cancer.
    Nielsen KV, Müller S, Møller S, Schønau A, Balslev E, Knoop AS, Ejlertsen B.
    Mol Oncol; 2010 Apr 15; 4(2):161-8. PubMed ID: 19945923
    [Abstract] [Full Text] [Related]

  • 13. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC.
    Clin Cancer Res; 2010 Apr 15; 16(8):2391-401. PubMed ID: 20371687
    [Abstract] [Full Text] [Related]

  • 14. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, Schonau A, Gunnarsdóttir K, Olsen KE, Mouridsen H, Ejlertsen B, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2005 Oct 20; 23(30):7483-90. PubMed ID: 16234514
    [Abstract] [Full Text] [Related]

  • 15. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer.
    Rody A, Karn T, Ruckhäberle E, Müller V, Gehrmann M, Solbach C, Ahr A, Gätje R, Holtrich U, Kaufmann M.
    Breast Cancer Res Treat; 2009 Feb 20; 113(3):457-66. PubMed ID: 18340528
    [Abstract] [Full Text] [Related]

  • 16. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays.
    Kauraniemi P, Bärlund M, Monni O, Kallioniemi A.
    Cancer Res; 2001 Nov 15; 61(22):8235-40. PubMed ID: 11719455
    [Abstract] [Full Text] [Related]

  • 17. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.
    Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grénman S, Isola J.
    Am J Pathol; 2000 Mar 15; 156(3):839-47. PubMed ID: 10702400
    [Abstract] [Full Text] [Related]

  • 18. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA, Vellon L, Lupu R.
    Int J Mol Med; 2006 Dec 15; 18(6):1081-7. PubMed ID: 17089011
    [Abstract] [Full Text] [Related]

  • 19. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.
    Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL.
    Oncogene; 1993 Apr 15; 8(4):933-8. PubMed ID: 8096076
    [Abstract] [Full Text] [Related]

  • 20. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E, Blomqvist C.
    Acta Oncol; 2006 Apr 15; 45(5):590-6. PubMed ID: 16864174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.